0.57

1.98% -0.0115

After Hours: .557 -0.013 -2.28%

Kiora Pharmaceuticals Inc (KPRX)

Overview News Price History Financials Discussions Forecast Stock Split

Kiora Pharmaceuticals Inc stock is currently priced at $0.57, with a 24-hour trading volume of 152.64K. It has seen a -1.98% decreased in the last 24 hours and a +12.60% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.5624 pivot point. If it approaches the $0.6091 resistance level, significant changes may occur.

Previous Close:

$0.5815

Open:

$0.6

24h Volume:

152.64K

Market Cap:

$14.97M

Revenue:

Net Income/Loss:

$-12.51M

P/E Ratio:

-0.0619

EPS:

-9.2108

Net Cash Flow:

$-9.56M

1W Performance:

+17.24%

1M Performance:

+12.60%

6M Performance:

-0.87%

1Y Performance:

-73.97%

1D Range:

$0.523

$0.60

52W Range:

$0.4511

$2.25

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Name

Kiora Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

781 788 9043

Address

332 Encinitas Boulevard, Suite 102, Encinitas

Employee

Twitter

Next Earnings Date

2024-05-14

Latest SEC Filings

KPRX's Discussions on Twitter

Kiora Pharmaceuticals Inc Stock (KPRX) Latest News

Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

KPRX Stock Price and Chart — NASDAQ:KPRX - TradingView

TradingView

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - StreetInsider.com

StreetInsider.com

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - Yahoo Finance

Yahoo Finance

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - Yahoo Finance

Yahoo Finance

EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy - The Globe and Mail

The Globe and Mail

Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data

Kiora Pharmaceuticals Inc (KPRX) Net Income 2024

KPRX net income (TTM) was -$12.51 million for the quarter ending December 31, 2023, a +7.87% increase year-over-year.

Kiora Pharmaceuticals Inc (KPRX) Cash Flow 2024

KPRX recorded a free cash flow (TTM) of -$9.56 million for the quarter ending December 31, 2023, a +8.35% increase year-over-year.

Kiora Pharmaceuticals Inc (KPRX) Earnings per Share 2024

KPRX earnings per share (TTM) was -$2.975 for the quarter ending December 31, 2023, a +88.51% growth year-over-year.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.